Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2026
Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 TrialJonathan So, Alexander Droznin, Payal Tiwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2025
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal CarcinomaZezhong Ye, Reza Mojahed-Yazdi, Anna Zapaishchykova, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaUmair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
JAMA Oncology|August 28, 2020
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical TrialJonathan D Schoenfeld, Glenn J Hanna, Vickie Y Jo, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2025
Adjuvant Radiation is Associated With Reduced Risks of Local Recurrence and Nodal Metastasis in High-Risk Localized Cutaneous Squamous Cell Carcinoma: A Retrospective Multicenter Cohort StudyNina A Ran, Emily E Granger, David G Brodland, et al.
The New England Journal of Medicine|October 26, 2007
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancerMarshall R Posner, Diane M Hershock, Cesar R Blajman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J Hanna, Anne O'Neill, Kee-Young Shin, et al.
Nature Communications|May 7, 2026
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trialGlenn J Hanna, Tulika R Gupta, Lorenzo Trippa, et al.
Pageof 10